As any therapeutic approach, including mTOR inhibitors in recurrent cervical cancer, would consider patients with recurrent disease for whom no standard therapy is available anymore, respective tissue samples may not perfectly depict the molecular and clinical behavior of very advanced cancers. The gene discussed is MTOR; the disease is cancer.